Australia's most trusted
source of pharma news
Posted 29 June 2026 AM
The TGA has approved Sanofi’s pegged blockbuster Altuviiio, Moderna’s latest Covid mRNA vaccine, plus the first generic versions of Ipsen’s Cabometyx and Takeda’s Revestive, both sponsored by Cipla.
Altuviiio, the first once-weekly factor VIII replacement intravenous infusion therapy for haemophilia A, made both Evaluate Vantage's analysis on new agents with blockbuster potential and Clarivate’s Drugs to Watch 2024 report, with the latter projecting the drug could earn US$1.77 billion in 2029.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.